Clik here to view.
Allegro Ophthalmics and Senju Pharmaceutical Announce Collaboration in Japan...
SAN JUAN CAPISTRANO, Calif. & OSAKA, Japan Allegro Ophthalmics, LLC and Senju Pharmaceutical Co., Ltd. today announced that they have entered into a collaboration and license agreement to...
View ArticleClik here to view.
Allegro Ophthalmicsと千寿製薬、血管性眼疾患に対する画期的新薬としてのインテグリン・ペプチド治療薬を日本で開発するための提携を発表
米カリフォルニア州サンホアンカピストラーノ & 大阪 （ビジネスワイヤ） — Allegro Ophthalmics,...
View ArticleClik here to view.
pSivida Corp. Announces Third Quarter 2013 Financial Results Release Date and...
WATERTOWN, Mass. pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its financial...
View ArticleClik here to view.
Hoya Reports Fourth Quarter and Full-Year Financial Results
TOKYO HOYA Corporation (TOKYO:7741) today announced financial results for the fourth quarter and full-year ended March 31, 2013. During the quarter, revenues from all operations increased 9.8% to...
View ArticleClik here to view.
Acucela and Otsuka Pharmaceutical Announce Phase IIa Clinical Results of...
SEATTLE & TOKYO Acucela Inc., a clinical-stage biotechnology company focused on developing therapies for sight-threatening diseases, and Otsuka Pharmaceutical Co., Ltd., (Otsuka) a Japan-based,...
View ArticleClik here to view.
大塚製薬とアキュセラ社...
米国ワシントン州シアトル市 & 東京 （ビジネスワイヤ） — 大塚製薬株式会社（本社：東京都千代田区、代表取締役社長：岩本太郎、以下「大塚製薬」）とAcucela Inc.（本社：米国ワシントン州シアトル、代表取締役会長・社長兼CEO：窪田良、以下「アキュセラ社」）は、本日、2013年度の視覚と眼科学研究協会会議（ARVO：Association for Research in...
View ArticleClik here to view.
R-Tech Ueno: Start of the Patient Enrollment of a Phase I/II Clinical Study...
TOKYO R-Tech Ueno, Ltd. (JASDAQ:4573): This is to announce start of the patient enrollment of the first stage of a Phase I/II clinical study of recombinant human serum albumin-containing ophthalmic...
View ArticleClik here to view.
NeuroVision Eye Test Part of Major Alzheimer’s Trial
SACRAMENTO, Calif. Researchers in Perth are trialling a NeuroVision eye test as a screening tool for Alzheimer’s disease. Professor Yogi Kanagasingam, a world leader in ocular imaging in CSIRO’s...
View ArticleClik here to view.
Investment Bridge Announces Investment Opinion: Bridge Report on R-Tech Ueno...
TOKYO Investment Bridge, one of Japan’s leading independent IR services companies, has released a “Bridge Report” on R-Tech Ueno, Ltd. (JASDAQ:4573) reviewing the fiscal year March 2013 earnings...
View ArticleClik here to view.
Proof Eyewear Will Be Opening a Rural Eye Clinic in Pathamadai, India
BOISE, Idaho Proof Eyewear is headed to Pathamadai, India to inaugurate the opening of the Proof Eye Clinic. Since its start in 2010, the company has been involved with a variety of causes such as...
View ArticleClik here to view.
SK Biopharmaceuticals and AriBio Enter into a Strategic Alliance
SEOUL, Korea The Korea-based international pharmaceutical company, SK Biopharmaceuticals, and the Korea-based emerging biotech, AriBio, announced that they entered into a collaboration agreement for...
View ArticleClik here to view.
Novaliq GmbH宣布其NovaTears™ OTC获准在欧盟上市
德国海德堡 (美国商业资讯)–Novaliq GmbH是一家研究投药的公司，专注于难溶眼科药物的外用，该公司今天宣布，其首款基于Novaliq的EyeSol™专利技术的外用眼科润滑剂成功获得CE认证。 NovaTears™ OTC是一种多剂量、非水性的外用滴眼液，用于润滑眼球表面，它不会引起视物模糊、也不含防腐剂。 Novaliq GmbH首席执行官Bernhard...
View ArticleClik here to view.
NovaliqがNovaTears™ OTCの欧州での販売承認を取得と発表
独ハイデルベルク （ビジネスワイヤ） — 難溶性薬物の眼科技術の局所適用に傾注するドラッグデリバリー企業のNovaliq GmbHは本日、Novaliqの専有技術EyeSol™を基盤にした初の局所用眼科粘稠剤でCEマークの認証取得に成功したと発表しました。 NovaTears™...
View ArticleClik here to view.
Hoya Announces First Quarter Financial Results
TOKYO HOYA Corporation (TOKYO:7741) today announced financial results for the first quarter ended June 30, 2013. For the quarter under review, revenues increased 8.4% to 100,425 million yen...
View ArticleClik here to view.
Ivantis Raises Additional $5 MM from Singapore-based Global Investor EDBI,...
IRVINE, Calif. Ivantis, developer of the novel Hydrus™ Microstent device designed to lower eye pressure for glaucoma patients, announced today that it secured an additional $5 MM in the second close...
View ArticleClik here to view.
Acucela Reaches 50% Enrollment in the Emixustat Hydrochloride Phase 2b/3...
SEATTLE Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for sight-threatening eye diseases, today announced that it has achieved 50% subject enrollment in...
View ArticleClik here to view.
アキュセラ社、エミクススタト塩酸塩の臨床第2b/3相試験 被験者登録数50%到達
SEATTLE 失明疾患の撲滅を目指し、革新的な新薬の開発に専念している眼科領域に特化したバイオ製薬企業アキュセラ社は、本日、地図状萎縮を伴うドライ型加齢黄斑変性患者を対象にしたエミクススタト塩酸塩の臨床第2b/3相試験（SEATTLE試験）の被験者登録数が、全体の50%に達したことを発表しました。SEATTLE試験（The Safety and Efficacy Assessment...
View ArticleClik here to view.
ブライアン･オカラガン氏の役員就任に関するお知らせ
SEATTLE （ビジネスワイヤ） — 失明疾患の撲滅を目指し、革新的な新薬の開発に従事している眼科領域に特化したバイオ製薬企業アキュセラ社は、本日、ブライアン・オカラガン氏を役員に任命したことを発表いたします。...
View ArticleClik here to view.
pSivida Corp. Reports Fourth Quarter and Fiscal Year 2013 Results
WATERTOWN, Mass. pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced financial results...
View ArticleClik here to view.
pSivida Announces That U.K.’s NICE Recommends ILUVIEN® for Chronic Diabetic...
WATERTOWN, Mass. pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, today...
View Article